Transitional Epidemiology of Human Papillomavirus Infection in Iran: A Cross-Sectional Study and National Review.

Malihe Hasanzadeh, Saeid Amel Jamehdar, Leila Mousavi Seresht, Mohammad Taghi Shakeri, Somaye Bolandi
Author Information
  1. Malihe Hasanzadeh: Department of Gynecology and Oncology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
  2. Saeid Amel Jamehdar: Department of Virology, Antimicrobial Resistance Research Center, Avicenna Research Institute, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  3. Leila Mousavi Seresht: Department of Gynecology and Oncology, Isfahan University of Medical Sciences, Hezarjarib Street, Isfahan, Iran.
  4. Mohammad Taghi Shakeri: Department of Biostatistics, Faculty of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
  5. Somaye Bolandi: Department of Gynecology and Oncology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Background: The high prevalence of cervical cancer in developing countries, despite its preventive nature, makes the disease a principal matter of concern for scientific studies. Providing global availability of primary and secondary preventive methods based on the high-risk human papillomavirus (HPV), which is the well-known pathogenesis in most malignant cervical lesions, has become the World Health Organization's (WHO's) critical target for 2030. Considering the demographic diversity and manufacturing of the internal vaccine in Iran, there is need for more study on the cost-effectiveness of these strategies.
Materials and Methods: This study intends to assess female HPV prevalence at the time in Iran provinces, especially in the capital province, Khorasan Razavi, in the north to establish a scientific rationale for conducting further studies on arguments for and against national HPV prevention strategies in line with the WHO. In this population-based study, the HPV prevalence was evaluated in 900 cervical samples accumulated between 2012 and 2015. The data were later compared with recently published data in the same province, in the north of Iran.
Result: Based on the results of our cross-sectional study, the estimated prevalence of HPV infection in the northern female population was 4.1% in 2015 and significantly increased to 35% in 2021.
Conclusion: The hypothesis of the impact of behavioral and cultural changes in addition to population aging on general health indicates the need for national health promotion strategies. Additionally, it emphasizes the critical significance of conducting further investigational studies to obtain the actual and updated prevalence of HPV in Iran.

Keywords

References

  1. Indian J Pathol Microbiol. 2010 Oct-Dec;53(4):681-5 [PMID: 21045392]
  2. Lancet. 2020 Feb 22;395(10224):575-590 [PMID: 32007141]
  3. Med Microbiol Immunol. 2017 Apr;206(2):105-110 [PMID: 27858157]
  4. Iran J Pathol. 2019 Summer;14(3):197-205 [PMID: 31582996]
  5. Iran J Cancer Prev. 2011 Summer;4(3):135-40 [PMID: 26328053]
  6. Infect Agent Cancer. 2018 Jan 25;13:6 [PMID: 29416557]
  7. J Pathol. 2014 Dec;234(4):441-51 [PMID: 25043390]
  8. Value Health Reg Issues. 2018 May;15:112-119 [PMID: 29698864]
  9. Infect Agent Cancer. 2022 Mar 5;17(1):7 [PMID: 35248145]
  10. CA Cancer J Clin. 2018 Nov;68(6):394-424 [PMID: 30207593]
  11. Int J Cancer. 2012 Jul 15;131(2):E156-61 [PMID: 22038830]
  12. Asian Pac J Cancer Prev. 2006 Oct-Dec;7(4):529-32 [PMID: 17250423]
  13. Int J Infect Dis. 2021 Feb;103:480-488 [PMID: 33310023]
  14. Semin Radiat Oncol. 2021 Oct;31(4):297-308 [PMID: 34455985]
  15. BMC Infect Dis. 2019 Jan 18;19(1):71 [PMID: 30658581]
  16. Iran J Public Health. 2011;40(3):113-21 [PMID: 23113093]
  17. Virol J. 2010 Mar 22;7:65 [PMID: 20302680]
  18. Asian Pac J Cancer Prev. 2019 Jul 01;20(7):1945-1949 [PMID: 31350949]
  19. Arch Iran Med. 2022 May 01;25(5):343-346 [PMID: 35943012]
  20. Clin Lab. 2014;60(2):267-73 [PMID: 24660540]
  21. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  22. Intervirology. 2017;60(4):125-130 [PMID: 29393201]
  23. J Low Genit Tract Dis. 2020 Apr;24(2):102-131 [PMID: 32243307]
  24. J Clin Diagn Res. 2015 Jul;9(7):IC01-IC02 [PMID: 26393145]
  25. Lancet Public Health. 2021 Jul;6(7):e510-e521 [PMID: 33864738]
  26. Bioimpacts. 2020;10(4):235-242 [PMID: 32983939]
  27. Intervirology. 2017;60(1-2):38-42 [PMID: 28723690]
  28. Vaccines (Basel). 2021 Apr 01;9(4): [PMID: 33916132]
  29. Gynecol Oncol Rep. 2017 Sep 01;22:16-20 [PMID: 28948205]
  30. Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3373-3377 [PMID: 29286606]
  31. Lancet. 2020 Feb 22;395(10224):591-603 [PMID: 32007142]
  32. Int J Reprod Biomed. 2017 May;15(5):305-310 [PMID: 28744526]
  33. Iran J Pathol. 2015 Summer;10(3):192-8 [PMID: 26351484]

Word Cloud

Created with Highcharts 10.0.0HPVprevalencecervicalIranstudystudiesstrategiespreventivescientifichumanpapillomaviruscriticalneedfemaleprovincenorthconductingnational2015datapopulationhealthEpidemiologyBackground:highcancerdevelopingcountriesdespitenaturemakesdiseaseprincipalmatterconcernProvidingglobalavailabilityprimarysecondarymethodsbasedhigh-riskwell-knownpathogenesismalignantlesionsbecomeWorldHealthOrganization'sWHO'starget2030Consideringdemographicdiversitymanufacturinginternalvaccinecost-effectivenessMaterialsMethods:intendsassesstimeprovincesespeciallycapitalKhorasanRazaviestablishrationaleargumentspreventionlineWHOpopulation-basedevaluated900samplesaccumulated2012latercomparedrecentlypublishedResult:Basedresultscross-sectionalestimatedinfectionnorthern41%significantlyincreased35%2021Conclusion:hypothesisimpactbehavioralculturalchangesadditionaginggeneralindicatespromotionAdditionallyemphasizessignificanceinvestigationalobtainactualupdatedTransitionalHumanPapillomavirusInfectionIran:Cross-SectionalStudyNationalReviewscreeninguterineneoplasmvaccination

Similar Articles

Cited By